Biotechnology News and Research

RSS

Athersys enters definitive agreements to sell common stock, warrants

Athersys, announced today that it has entered into definitive agreements with certain investors to sell 4,366,667 shares of its common stock and warrants to purchase up to an additional 1,310,000 shares of common stock in a registered direct offering for gross proceeds of approximately $13.1 million, before deducting fees and offering expenses.

29 Jan 2011

BGU, PTT sign R&D collaboration agreement for commercial development of green algae strain

Ben-Gurion University of the Negev and the PTT Chemical Public Company Ltd. in Thailand have signed a research and development collaboration agreement for commercial development of BGU's proprietary green algae strain.

29 Jan 2011

HBA to honor Pfizer chief medical officer as its 2011 Woman of the Year

The Healthcare Businesswomen's Association announced that its 2011 "Woman of the Year" is Freda Lewis-Hall, MD, chief medical officer of Pfizer. In her distinguished 30-year career, Dr. Lewis-Hall has held leadership roles in direct patient care, academics, media, government, pharmaceuticals and biotechnology.

29 Jan 2011

BioTime announces acquisition of CTI assets

BioTime, today announced that it has acquired substantially all the assets of Cell Targeting, a Cleveland, Ohio-based biotechnology company conducting research in regenerative medicine.

29 Jan 2011

FDA approves Arteriocyte's Magellan MAR01 technology for Phase I trial to treat CLI

Arteriocyte, a leading clinical stage biotechnology company with offices in Cleveland, Ohio and Hopkinton, Massachusetts that develops proprietary stem cell and tissue engineering based therapies, announced today approval from the Food and Drug Administration to initiate a Phase I clinical trial using its Magellan MAR01 technology in the treatment of Critical Limb Ischemia.

29 Jan 2011

Genentech, Biogen announce FDA approval of Rituxan to treat follicular lymphoma

Genentech, a member of the Roche Group, and Biogen Idec today announced the U.S. Food and Drug Administration approved Rituxan as a maintenance treatment for patients with advanced follicular lymphoma who responded to initial treatment with Rituxan plus chemotherapy.

28 Jan 2011

EHSI examines business plans and product lines of OceanBASIS

Emerging Healthcare Solutions, Inc. is examining the business plans and product lines of German biotech firm OceanBASIS as part of the company's due diligence towards a potential profit sharing agreement.

28 Jan 2011

Tarceva Phase III EURTAC study in NSCLC patients with EGFR activating mutations meets primary endpoint

Genentech, a member of the Roche Group and OSI Pharmaceuticals, a wholly owned subsidiary of Astellas U.S. Holding Inc., a holding company owned by Astellas Pharma Inc., today announced that an independent data monitoring committee has recommended that the Phase III EURTAC study be stopped early because the study met its primary endpoint.

28 Jan 2011

Cetero Research completes 20,000th early-phase clinical study

Cetero Research, the leading early-stage contract research organization, today announced that it has reached another industry milestone with the completion of its 20,000th early-phase clinical study.

28 Jan 2011

ALS Biopharma receives ADDF grant to develop therapeutics against Alzheimer's disease

The Alzheimer's Drug Discovery Foundation announced today that it has awarded a grant of $195,000 to ALS Biopharma, LLC to develop therapeutics targeted at clearing toxic proteins implicated in Alzheimer's disease.

28 Jan 2011

FDA schedules fourth orphan drug designation workshop

The U.S. Food and Drug Administration has scheduled its fourth orphan drug designation workshop for academics, biotechnology companies, and those unfamiliar with the process for Feb. 28 – March 1, 2011, in Claremont, Calif. in collaboration with Keck Graduate Institute.

28 Jan 2011

Disabled and elderly people can benefit from new hand-held computer

Disabled and elderly people could find it easier to navigate around town and city centres with a new hand-held computer being developed by a geographical information systems professor at Kingston University in South West London.

27 Jan 2011

Baxter fourth quarter net income declines 26% to $423 million

Baxter International Inc. today announced its financial results for the fourth quarter of 2010, and provided its financial outlook for the first quarter and full-year 2011.

From Baxter International Inc. 27 Jan 2011

SRI awarded DOE grant to expand MetaCyc database and enhance Pathway Tools software

SRI International, an independent nonprofit research and development organization, announced today it has been awarded a grant by the Department of Energy (DOE) to expand its MetaCyc database and enhance its Pathway Tools software. This project will give SRI's bioinformatics tools even greater utility in the emerging area of bioenergy, or renewable energy derived from biological sources.

27 Jan 2011

Merck Canada invests in CQDM to support biopharmaceutical research

Merck Canada has renewed its partnership with the Quebec Consortium for Drug Discovery by investing a further $5 million over five years in the organization so it can continue its support of biopharmaceutical research in Quebec.

27 Jan 2011

Study: Removal of B lymphocytes can reverse aging process

Researchers at the Technion-Israel Institute of Technology have discovered a way to reverse the aging process by removing old B lymphocytes from old mice, and forcing the production of young, potent cells to replace them.

27 Jan 2011

QIAGEN announces formation of subsidiary in India

QIAGEN today announced the formation of its India subsidiary, QIAGEN India Pvt. Ltd., and the beginning of direct sales in the country. Until now, QIAGEN products have been sold in India through distributor partnerships.

From QIAGEN Manchester Limited 27 Jan 2011

FDA, Simulations Plus sign RCA to develop QSAR toxicity models

Simulations Plus, a leading provider of software for pharmaceutical discovery and development, announced that the U.S. Food and Drug Administration and Simulations Plus have signed a five-year research collaboration agreement to work together to develop Quantitative Structure-Activity Relationship toxicity models for FDA regulatory and research applications.

27 Jan 2011

Teva announces acquisition of Corporación Infarmasa

Teva Pharmaceutical Industries Ltd. announced today the acquisition of Corporación Infarmasa, a top ten pharmaceutical company in Perú, from The Rohatyn Group and Altra Investments.

27 Jan 2011

New four year study to evaluate asthma triggers in children

A newly announced study by researchers at UMDNJ-Robert Wood Johnson Medical School will examine how elevated levels of exposure to air pollutants, coupled with chronic psychological stress, may contribute to higher rates of asthma in urban communities.

27 Jan 2011